Patents for A61P 35 - Antineoplastic agents (221,099)
04/2007
04/25/2007CN1311833C Inhibition of the growth factor dependency of tumor cells
04/25/2007CN1311832C Medicinal use of bromodihydroarteannuin
04/25/2007CN1311826C Nano composition of 9-nitrocamptothecin lipoid and its preparation
04/25/2007CN1311823C Indirubin phosphatide compound and its preparation method
04/25/2007CN1311818C Pharmaceutical composition for solid tumour
04/25/2007CN1311817C Solid tumor treating medicine composition
04/24/2007US7208629 5′-Carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
04/24/2007US7208598 Trans-N2-(4-aminocyclohexyl)-N6-[2-[[[4-choro-3-trifluoromethyl)-phenyl]-methyl]-amino]-ethyl]-9-cyclopentyl-9H-purin-2,6-diamine trihydrochloride; cycline-dependent kinase proteins (cdk) inhibitor; animitotic, antitumor agents
04/24/2007US7208582 Polynucleotides codes for antibodies having amino acid sequences selected from complementary determining regions of variable peptides or single chain fragments, used as anticarcinogenic agents
04/24/2007US7208521 Selective inhibitors of the urokinase plasminogen activator
04/24/2007US7208514 Phenylpyrazole compounds such as 1-(3-cyano-4-neopentyloxyphenyl)pyrazole-4-carboxylic acid and the like for preventing colon cancer and the like, and as an agent for suppressing tumorigenesis
04/24/2007US7208513 Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
04/24/2007US7208500 Treating hyperproliferative disorders; N-(4,6-Dimethyl-pyridin-2-yl)-2-{3-fluoro-4-[2-(1-methyl- 1H-imidazol-2-yl)-thieno[3,2-b]pyridin-7-yloxy]-phenyl}-acetamide for example; receptor kinase inhibitors
04/24/2007US7208498 Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
04/24/2007US7208491 N-monoacylated o-phenylenediamines
04/24/2007US7208489 2-(pyridin-2-ylamino)-pyrido [2,3-d]pyrimidin-7-ones
04/24/2007US7208477 Treatments for benign tumors, cancers, neoplasias, and/or other inflammatory disorders or diseases
04/24/2007US7208280 Controlling gene expression in tissue
04/24/2007US7208279 Method for identifying inhibitors of G protein coupled receptor signaling
04/24/2007US7208270 Detecting demyelinating nervous system disorder by measurement of stem cell factor (SCF)-apoptosis-response gene protein(SARG-1-) protein; antiproliferative agents; microtubule associated protein 1(map1a); cancer screening
04/24/2007US7208267 Compositions and methods relating to breast specific genes and proteins
04/24/2007US7208146 Vaccine comprising at least two recombinant variable regions of immunoglobulin molecules derived from B-cell lymphoma cells, wherein cells express at least two different immunoglobulin molecules differing by one idiotype
04/24/2007CA2403902C Malonamic acids and derivatives thereof as thyroid receptor ligands
04/24/2007CA2281545C N-heterocyclic derivatives as nos inhibitors
04/24/2007CA2236482C Expression of cyclin g1 in tumors
04/24/2007CA2184345C Coordinate in vivo gene expression
04/24/2007CA2091346C Methods and compositions for genetic therapy and potentiation of anti-tumor immunity
04/24/2007CA2073855C Glycoalkaloids for controlling cellular autophagy
04/19/2007WO2007044813A1 PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
04/19/2007WO2007044779A1 Kinase inhibitors
04/19/2007WO2007044698A1 PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
04/19/2007WO2007044449A2 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
04/19/2007WO2007044426A2 Pyrazolopyrimidines as protein kinase inhibitors
04/19/2007WO2007044420A1 Pyrazolopyrimidines as cyclin dependent kinase inhibitors for the treatment of cancer
04/19/2007WO2007044410A1 Pyrazolo [1,5-a] pyrimidines as protein kinase inhibitors
04/19/2007WO2007044407A2 Pyrazolo (1 , 5a) pyrimidines as protein kinase inhibitors
04/19/2007WO2007044401A2 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
04/19/2007WO2007044015A1 Treating or preventing renal cancer using a dimethane sulfonate
04/19/2007WO2007043715A1 Rna-binding peptide
04/19/2007WO2007043640A1 Substance for use in treatment or prevention of hcv infection
04/19/2007WO2007043635A1 Preventive/remedy for cancer
04/19/2007WO2007043630A1 Nkt cell-stimulating agent for administration through upper respiratory tract mucous membrane
04/19/2007WO2007043629A1 Method of inhibiting angiogenesis by using ephrin b2
04/19/2007WO2007043580A1 Iontophoresis preparation for treatment of breast cancer and/or mastitis
04/19/2007WO2007043568A1 S1p3 receptor antagonist
04/19/2007WO2007043401A1 Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
04/19/2007WO2007043400A1 Nitrogenated aromatic heterocyclic compound and pharmaceutical composition comprising the same
04/19/2007WO2007042912A2 Heterocyclic compounds as pstat3/il-6 inhibitors
04/19/2007WO2007042851A1 Optimizing malignant disease-free survival by combined modality treatment
04/19/2007WO2007042810A1 Pyrimidine derivatives for the treatment of cancer
04/19/2007WO2007042806A1 Pyrimidine derivatives for the treatment of cancer
04/19/2007WO2007042799A1 Novel crystalline forms
04/19/2007WO2007042786A2 4 -heteroaryl pyrimidine derivatives and use thereof as protein kinase inhibitors
04/19/2007WO2007042775A2 Conjugates of photosensitisers and antibodies
04/19/2007WO2007042647A1 Erythrocytes containing 5-fluorouracil (5-fu) and/or oxaliplatinum
04/19/2007WO2007042430A1 Regimen of administration for 5-(2-chlorophenyl)-1 ,2-dihydro-7-fluoro-8-methoxy-3-methyl-pyrazolo [3, 4.-b] [1, 4] benzodiazepine
04/19/2007WO2007042289A2 Nanobodies™ and polypeptides against egfr and igf-ir
04/19/2007WO2007041986A1 Antimitotic rhizoxin derivatives of burkholderia rhizoxina, method for producing said derivatives and use thereof
04/19/2007WO2007041965A1 The application of trpc in screening anti-tumor medicaments and the pharmaceutical use of its inhibitor
04/19/2007WO2007041951A1 Extraction method of abalone polysaccharide
04/19/2007WO2007041950A1 Extraction method of patinopecten yessoensis polysaccharide
04/19/2007WO2007041832A1 Use of liposomes in a carrier comprising a continuous hydrophobic phase as a vehicle for cancer treatment
04/19/2007WO2007022635A3 Methods of attenuating prostate tumor growth by insulin-like growth factor binding protein-3 (igfbp-3)
04/19/2007WO2007017758A3 Novel cysteine protease inhibitors and their therapeutic applications
04/19/2007WO2007017758A2 Novel cysteine protease inhibitors and their therapeutic applications
04/19/2007WO2007015923A3 Benzimidazoles useful as inhibitors of protein kinases
04/19/2007WO2007011629A3 Synthesis and complete stereochemical assignment of psymberin/irciniastatin for anti-tumor use
04/19/2007WO2007009734A3 Combination preparation, particularly for treating prostate cancer
04/19/2007WO2007007152A3 Anti-madcam antibodies to treat metastatic cancers and chloroma
04/19/2007WO2007006797A8 Use of 4-(3,4-dichloro-phenyl)-1,2,3,4-tetrahydro-naphtalen-1-ylamine for treating cancer
04/19/2007WO2007002223A3 Cd19 antibodies and their uses
04/19/2007WO2006133398A3 In vitro activated donor t-cells to promote transplant engraftment
04/19/2007WO2006125813A3 Tetrahydropyridothiophenes for use in the treatment of cancer
04/19/2007WO2006123185A3 Sulphamides for treatment of cancer
04/19/2007WO2006123184A3 Sulphonamido-substituted cyclohexyl sulphones for treatment of cancer
04/19/2007WO2006118973A3 Methods of using heterobyclic compounds for treatment of rectal cancer
04/19/2007WO2006116592A3 Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
04/19/2007WO2006115413A3 Methods and means for the treatment of hpv induced intraepithelial neoplasias
04/19/2007WO2006084210A3 Hif modulating compounds and methods of use thereof
04/19/2007WO2006078942A3 Regulation of protein synthesis by inhibition of eif4e-eif4g interaction
04/19/2007WO2006076678A3 Prostate stem cell antigen vaccines and uses thereof
04/19/2007WO2006071983A9 Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
04/19/2007WO2006055697A3 Cancer immunotherapy incorporating p53
04/19/2007WO2005111234A3 Methods of using zc1 and zc3 kinase substrate phosphorylation as biomarkers
04/19/2007WO2005056802A3 Materials and methods relating to cell cycle control
04/19/2007US20070089176 Cytokine involved in epithelial-mesenchymal transition
04/19/2007US20070088085 Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands
04/19/2007US20070088068 E-series of prostaglandin (EP) receptors; reducing [4-(4,9-dipropoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]acetate to form [[4-(4,9-dipropoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl) phenyl]acetic acid
04/19/2007US20070088062 N-[4-[2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl]phenyl]-2-benzothiazolamine; keratinization disorder such as rosacea, acne, and psoriasis; potent inhibitors of the retinoic acid-metabolism; show little or no endocrinological side-effects;
04/19/2007US20070088044 Quinazoline derivatives as antitumor agents
04/19/2007US20070088037 Cancer and fibrotic diseases
04/19/2007US20070088033 Diaryl Substituted Pyridinones
04/19/2007US20070088008 treating psoriasis with e.g. 19-nor-2beta-ethyl-1alpha,25-dihydroxyvitamin D3
04/19/2007US20070087999 Pharmaceutical compositions containing cyclodextrins and taxoids
04/19/2007US20070087375 Methods and compositions for treating cancer using 2192, 2193, 6568, 8895, 9138, 9217, 9609, 9857, 9882, 10025, 20657, 21163, 25848, 25968, 32603, 32670, 33794, 54476 and 94710
04/19/2007US20070087342 Secreted proteins
04/19/2007US20070086998 Therapeutic human anti-mhc class II antibodies and their uses
04/19/2007US20070086985 Vectors for tissue-specific replication
04/19/2007US20070086984 Viruses for the Treatment of Cellular Proliferative Disorders
04/19/2007US20070086973 Drug delivery systems for photodynamic therapy